NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, B. Andreadis, Nancy L. Bartlett, Lihua E. Budde, Paolo F. Caimi, Julie Chang, Beth Christian, Sven deVos, Bhagirathbhai Dholaria, Luis Fayad, Thomas M. Habermann, Muhammad Saad Hamid, Francisco J. Hernandez‐Ilizaliturri, Boyu Hu, Mark Kaminski, Yasmin Karimi, Chris R. Kelsey, Rebecca L. King, Susan Krivacic, Ann S. LaCasce, Megan S. Lim, Marcus Messmer, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph M. Tuscano, Julie M. Vose, Mary A. Dwyer, Hema Sundar
Abstract
Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.